ADARs Edit MicroRNAs to Promote Leukemic Stem Cell Activity.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27494666.
- Also identified by DOI 10.1016/j.stem.2016.07.012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Leukemic stem cells (LSCs) drive progression of chronic myeloid leukemia (CML) and tyrosine kinase inhibitor resistance through poorly understood mechanisms. Now in Cell Stem Cell, Zipeto et al. (2016) show targeting the RNA editing enzyme ADAR1 restores expression of let-7 and efficiently kills LSCs, providing an innovative therapeutic target in CML.
Medical subject headings
- MicroRNAs
- Neoplastic Stem Cells